Cyclopharm Ltd CYC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- A$0.48
- Day Range
- A$0.46–0.49
- 52-Week Range
- A$0.44–1.29
- Bid/Ask
- A$0.46 / A$0.51
- Shares Outstanding
- 125.73M
- Market Cap
- A$57.84M
- Volume/Avg
- 169,702 / 72,884
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3.06
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Cyclopharm Ltd is a health technology company offering solutions related to functional lung ventilation imaging. Its proprietary product Technegas is a broad-spectrum diagnostic lung imaging technology product for the visualisation of pulmonary ventilation and lung function. The company sells its products to healthcare institutions and medical professionals. Maximum revenue is generated from its Technegas products and services, which include the sale of diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. Geographically, the company generates maximum revenue from its business in Europe, and the rest from Asia Pacific, Canada, the USA, and other regions.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Value
- Total Number of Employees
- 63
- Website
- https://cyclopharm.com.au
Valuation
|
Metric
|
CYC
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.82 |
Price/Sales | 3.06 |
Price/Cash Flow | — |
Price/Earnings
CYC
Financial Strength
|
Metric
|
CYC
|
|---|---|
Quick Ratio | 2.05 |
Current Ratio | 3.37 |
Interest Coverage | −30.97 |
Quick Ratio
CYC
Profitability
|
Metric
|
CYC
|
|---|---|
Return on Assets (Normalized) | −33.92% |
Return on Equity (Normalized) | −54.12% |
Return on Invested Capital (Normalized) | −42.38% |
Return on Assets
CYC
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| LOCK|#%!fZ% | LOCK|qPhK | $172B | |||
| Medtronic PLC
MDT
| LOCK|%vm#Rs# | LOCK|d?!>T | $113B | |||
| Stryker Corp
SYK
| LOCK|<^>CBMc | LOCK|$<! | $106B | |||
| Boston Scientific Corp
BSX
| LOCK|<J&TKKq | LOCK|clW?x | $62B | |||
| Edwards Lifesciences Corp
EW
| LOCK|D$?VpB< | LOCK|>F@K# | $49B | |||
| DexCom Inc
DXCM
| LOCK|LnB@mW^ | LOCK|T#^dh | $32B | |||
| GE HealthCare Technologies Inc Common Stock
GEHC
| LOCK|jL$?%>V | LOCK|^c | $30B | |||
| Koninklijke Philips NV ADR
PHG
| LOCK|VCg | LOCK|^Fx | $24B | |||
| Steris PLC
STE
| LOCK|$fx?qcX | LOCK|C&<< | $21B | |||
| Zimmer Biomet Holdings Inc
ZBH
| LOCK|>cfy$Mr | LOCK|Mq> | $17B |
United States